Abstract

Crohn’s disease is a chronic, idiopathic condition characterized by intestinal inflammation and debilitating gastrointestinal symptomatology. Previous studies of inflammatory bowel disease (IBD), primarily in colitis, have shown reduced inflammation after electrical or pharmacological activation of the vagus nerve, but the scope and kinetics of this effect are incompletely understood. To investigate this, we studied the effect of electrical vagus nerve stimulation (VNS) in a rat model of indomethacin-induced small intestinal inflammation. 1 min of VNS significantly reduced small bowel total inflammatory lesion area [(mean ± SEM) sham: 124 ± 14 mm2, VNS: 62 ± 14 mm2, p = 0.002], intestinal peroxidation and chlorination rates, and intestinal and systemic pro-inflammatory cytokine levels as compared with sham-treated animals after 24 h following indomethacin administration. It was not known whether this observed reduction of inflammation after VNS in intestinal inflammation was mediated by direct innervation of the gut or if the signals are relayed through the spleen. To investigate this, we studied the VNS effect on the small bowel lesions of splenectomized rats and splenic nerve stimulation (SNS) in intact rats. We observed that VNS reduced small bowel inflammation also in splenectomized rats but SNS alone failed to significantly reduce small bowel lesion area. Interestingly, VNS significantly reduced small bowel lesion area for 48 h when indomethacin administration was delayed. Thus, 1 min of electrical activation of the vagus nerve reduced indomethacin-induced intestinal lesion area by a spleen-independent mechanism. The surprisingly long-lasting and spleen-independent effect of VNS on the intestinal response to indomethacin challenge has important implications on our understanding of neural control of intestinal inflammation and its potential translation to improved therapies for IBD.

Highlights

  • Crohn’s disease and ulcerative colitis are two debilitating inflammatory bowel diseases (IBD) characterized by abdominal pain, weight loss, and frequent bowel movements

  • The hallmarks of Crohn’s disease are the involvement of the small bowel and the transmural inflammation in contrast to ulcerative colitis, which is limited to the colon and presents as a more superficial intestinal inflammation with bloody stools

  • Rats were subjected to cervical vagus nerve stimulation (VNS) or sham stimulation followed by subcutaneous injection of indomethacin

Read more

Summary

Introduction

Crohn’s disease and ulcerative colitis are two debilitating inflammatory bowel diseases (IBD) characterized by abdominal pain, weight loss, and frequent bowel movements. Many of the therapeutic options involve systemic immunosuppressive drugs with potential long-term adverse effects such as infections and malignancies (Dignass et al, 2012; Torres et al, 2019). There is an unmet need to improve effective treatment of Crohn’s disease while minimizing risks of serious side effects. This is important in young patients who will require years of immunosuppressive maintenance treatment to keep the disease in remission. There is increasing evidence that neural reflexes regulate gut inflammation in health and disease, suggesting that targeting neural circuits is a potential therapeutic option in IBD (Goverse et al, 2016; Stakenborg and Boeckxstaens, 2021)

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call